ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure
Assembly Biosciences, Inc. (the Company) is furnishing a
corporate presentation, attached as Exhibit 99.1 to this Current
Report on Form 8-K, which the Company intends to use from time to
time in meetings with investors and others beginning on January
9, 2017. The corporate presentation will also be available on the
Companys website at http://investor.assemblybio.com/index.cfm.
The information in this Item 7.01 and Exhibit 99.1 attached
hereto is intended to be furnished and shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibit relating to Item 7.01 shall be deemed
furnished, and not filed:
| Exhibit No. | Description | |
| 99.1 |
Assembly Biosciences, Inc. Corporate Presentation January 2017. |
|
About ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections. ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB) Recent Trading Information
ASSEMBLY BIOSCIENCES, INC. (NASDAQ:ASMB) closed its last trading session down -0.62 at 12.19 with 17,949 shares trading hands.